Introduction
Cigarette smoking is considered a major risk factor for vascular diseases based on atherosclerosis. [1] [2] [3] [4] Although the mechanisms of atherogenesis induced by cigarette smoking are still not fully understood, endothelial injury and dysfunction are considered to play major roles in the aetiology of smoking-induced atherosclerosis. It has been reported that smoking causes short-term impairment of coronary vasodilator capacity even in young healthy smokers, 5 followed by a reduction of endothelium-dependent vasodilatation, 6 resulting in increased frequency and duration of coronary ischaemia. 7 Such clinical evidence is also supported by several basic reports: (1) oxidative stress, a major risk factor for endothelial damage, is induced by cigarette smoking, 8 (2) cigarette smoking reduces eNOS activity in cultured endothelial cells, 8 and (3) cigarette smoking impairs maintenance of the endothelium by inhibition of endothelial cell migration. 9 Thus, it is important to evaluate pharmacological agents that have endothelial protective actions in hypertensive smokers.
From these viewpoints, calcium antagonists are interesting, since their administration has beneficial effects on endothelial damage. 10, 11 The mechanisms are thought to be through the induction of NO production. 12 Especially, nifedipine, a calcium antagonist that is often used clinically, is considered to have protective effects on endothelial cells, since previous reports revealed improvement of endothelial dysfunction in hypertensive patients. In addition, several megatrials demonstrated that nifedipine inhibited the progression of atherosclerosis in the coronary arteries. 13, 14 However, it is still unclear whether nifedipine improves endothelial dysfunction by direct effects or indirect effects such as reduction of blood pressure (BP). To clarify this point, we examined the effects of nifedipine on endothelial dysfunction caused by cigarette smoking in patients without any other risk factors for atherosclerosis. Moreover, we also focused on the effect of nifedipine on hepatocyte growth factor (HGF), since HGF is a novel angiogenic growth factor with antiapoptotic effects on endothelial cells.
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Materials and Methods
Study design
The subjects were 10 male smokers without hypertension aged 30-40 years (3572 years) and 10 ageand sex-matched normotensive smokers as placebo control. Subjects with diabetes mellitus, hyperlipidaemia or any other disease were excluded by clinical and laboratory examinations. No subjects were receiving any medical treatment. This study was performed under written informed consent.
Forearm blood flow (FBF) was measured by straingauge plethysmography after 2 and 4 weeks of nifedipine (20 mg) or placebo treatment administered once a day. Serum HGF concentration was also measured by EIA after 2 and 4 weeks of drug treatment. To exclude the effect of the drug on contraction of smooth muscle cells, examinations were performed after a wash-out period of 3 days. After the measurement of pretreatment parameters, the drug was administered for 2 weeks and withdrawn for 3 days, followed by measurement of parameters. This series was repeated.
Measurement of FBF
The study was conducted in a temperature-controlled dark quiet room. Subjects rested for 15 min in the supine position before measurement. A straingauge plethysmograph (EC5R, DE Horkkanson, Inc., WA, USA) was employed to measure FBF. The procedure has been previously published in detail. 17 Reactive hyperaemia ratio was calculated as hyperaemia/baseline value of FBF, reflecting endothelium-dependent vasodilatation. The nitroglycerin-induced hyperaemia/baseline value of FBF was calculated as endothelium-independent vasodilatation.
Blood sampling and HGF measurement
Antecubital venous blood was taken during the morning hours, 0700-0900, after an overnight fast. Serum was immediately separated by centrifugation at 41C, and stored at À201C until assay. Serum HGF concentration was assayed using a recently developed EIA for use in humans. The procedure has been previously published in detail. 18 
Materials
Nifedipine was obtained from Bayer (Osaka, Japan). A long-acting preparation of nifedipine that was active for 24 h was used.
Statistical analysis
All values are expressed as mean 7s.e.m. Analysis of variance with subsequent Duncan's test was used to determine the significance of differences in multiple comparisons. Differences with values of Po0.05 were considered significant.
Results
The clinical characteristics of the subjects are shown in Table 1 . The subjects were treated with nifedipine monotherapy (20 mg, n ¼ 10) or placebo (n ¼ 10) for 4 weeks. We measured BP at the same time as the blood flow response was determined (after a washout period of 3 days), and nifedipine did not affect BP and heart rate in normotensive smokers (systolic BP: pre; 111.473.0, 2W; 104.674.6, 4W; 108.272.0 (mmHg), diastolic BP: pre; 62.274.0, 2W; 57.375.1, 4W; 58.072.8 (mmHg), HR: pre; 68.174.0, 2W; 72.375.3, 4W; 71.172.9 (/min)). Although there was no significant change in reactive hyperaemia ratio in subjects with placebo, administration of nifedipine for both 2 and 4 weeks resulted in a significant increase in reactive hyperaemia ratio (Figure 1a) . Nitroglycerin-induced hyperaemia ratio was not changed in either group (Figure 1b) , demonstrating that the effect of nifedipine was mediated by improvement of endothelial function. These data suggest that nifedipine has direct Values are mean7s.e.m.
Effect of nifedipine on endothelial function in smokers K Yamasaki et al beneficial effects on smoking-induced endothelial dysfunction, independent of the reduction in BP. Unexpectedly, serum hepatocyte growth factor (HGF) concentration in nifedipine-treated smokers was significantly elevated after 2-and 4-week treatment as shown in Table 2 . As shown in Figure 2 , increase in serum HGF concentration tended to be related to improvement of reactive hyperaemia ratio (r ¼ 0.207).
Discussion
The pathophysiological role of endothelial cells is important, since locally synthesized compounds from endothelial cells and vascular smooth muscle cells (VSMC) have been postulated to control local vascular function. [19] [20] [21] [22] [23] From this viewpoint, the maintenance of endothelial cells is very important, given their antiproliferative and vasodilating actions. Indeed, disruption or dysfunction of endothelial cells results in loss of multiple endothelium-derived substances (PGI 2 , NO, CNP), resulting in a shift of balance of VSMC growth to abnormal growth such as in atherosclerosis. Cigarette smoking is one of the major risk factors for atherogenesis, since it causes loss of the vasodilating properties of resistance vessels, as described above. A major finding of the current study is that nifedipine directly improved smoking-induced endothelial dysfunction without a reduction of BP. More importantly, a beneficial response to nifedipine was observed even at the early stage, after 2 weeks of administration.
Interestingly, the present study showed an increase of circulating HGF level by the administration of nifedipine. As a local HGF system (HGF and its receptor, c-met) has been identified in vascular cells, 24 HGF may have an important role in the pathophysiology of vascular diseases. Indeed, our previous data showed that the vascular HGF concentration in spontaneously hypertensive rats (SHR) was significantly lower than that in WistarKyoto rats (WKY), while serum HGF concentration was increased as a systemic compensatory mechanism in SHR as compared to WKY. 25 Moreover, our previous report demonstrated that the area covered by endothelial cells in rat balloon-injured vessels was significantly increased by in vivo transfer of the HGF gene. 26 We also demonstrated that Effect of nifedipine on endothelial function in smokers K Yamasaki et al administration of cilostazol improved endotheliumdependent vascular relaxation through induction of serum HGF in rat balloon-injured vessels. 27 These data, including the present findings, are consistent with our previous in vitro findings that the downregulation of HGF is caused by downregulated c-AMP and/or upregulated TGF-b in a hypoxic or high glucose condition which promotes atherosclerosis, and addition of HGF could rescue endothelial cells from death. 28, 29 Therefore, supplemental HGF would physiologically improve endothelial dysfunction of vessels induced by smoking. Since the serum HGF level was increased approximately two-fold by nifedipine, it is considered to be effective for vascular tissue and endothelial cells. 27 Systemic HGF may function in tissue regeneration as a humoral mediator, in addition to autocrine-paracrine local HGF production, and may act protectively against endothelial dysfunction in organs such as the vasculature. Although we failed to clarify how nifedipine increased serum HGF concentration in the present study, the increase in circulating HGF by nifedipine would be considered to contribute to the prevention of vascular complications in smokers with hypertension.
Overall, the present study demonstrated direct effects of nifedipine on smoking-induced endothelial dysfunction. Given the protective actions of HGF against endothelial injury, increased circulating HGF by nifedipine may contribute to the improvement of endothelial dysfunction.
Study limitations
The present investigation has several limitations. First, since we measured BP after a wash-out period of 3 days, it is not certain that there was no alteration in BP throughout the period of this study because we did not perform 24-h ambulatory monitoring. Second, reactive hyperaemia mainly represents postischaemic vasoreactivity but also partly reflects endothelium-dependent vasodilation. Third, the present data show a discrepancy with most previous reports in which flow-dependent vasodilation but not reactive hyperaemia was disturbed in normotensive smokers. We consider that an additional method is required to evaluate the effect of nifedipine on endothelial function, such as measurement of flow and diameter of the brachial artery with wrist occlusion by an ultrasound system. Fourth, the size of the investigation was small. We consider that a large randomized, double-blinded trial is required. Also, to study our hypothesis in detail, a nonsmoker group treated with nifedipine is needed.
